Inheritability of Leiomyosarcoma
Most leiomyosarcomas are sporadic and not hereditary, but specific hereditary syndromes—particularly Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) syndrome and hereditary retinoblastoma—do confer increased risk for leiomyosarcoma development. 1
Hereditary Syndromes Associated with Leiomyosarcoma
HLRCC Syndrome (Primary Hereditary Association)
HLRCC is caused by germline mutations in the fumarate hydratase (FH) gene and represents the most direct hereditary link to leiomyosarcoma. 1 This autosomal dominant syndrome is characterized by:
- Cutaneous leiomyomas (benign smooth muscle tumors of the skin)
- Uterine leiomyomas (fibroids), often severe and requiring surgery before age 40
- Renal cell carcinoma (papillary type 2, collecting duct, or tubulopapillary)
- Rare progression to leiomyosarcoma (occurs in <1% of HLRCC patients) 2, 3
The mutation detection rate is high: 85% of individuals with cutaneous leiomyomas have FH mutations 1. While leiomyosarcoma development is uncommon in HLRCC, it does occur, particularly in uterine tissue, though the exact syndromic association remains uncertain 3.
Hereditary Retinoblastoma
Germline RB1 mutations causing hereditary retinoblastoma significantly increase leiomyosarcoma risk. 4 Leiomyosarcoma is the most frequent soft tissue sarcoma subtype in these patients, with 78% diagnosed ≥30 years after retinoblastoma diagnosis 4. Importantly, this risk exists even without radiation therapy, indicating genetic predisposition independent of treatment 4.
For uterine leiomyosarcoma specifically in retinoblastoma survivors, the standardized incidence ratio is 277 (95% CI: 90-646), with diagnosis ages ranging from 32-51 years 5. However, surveillance for uterine leiomyosarcoma is not recommended even in this high-risk population due to lack of effective screening modalities 5.
Other Hereditary Associations
Li-Fraumeni syndrome (TP53 mutations) increases risk for various sarcomas including leiomyosarcoma, though this is less specific than HLRCC 4, 6.
When Genetic Testing/Counseling Is Indicated
Specific Referral Criteria for HLRCC
Refer for genetic counseling any individual with: 1
- Cutaneous leiomyomas (multiple skin lesions)
- Renal cell carcinoma with characteristic histology (papillary type 2, collecting duct, or tubulopapillary)
- First-degree relative with either of the above
Additional Red Flags Warranting Evaluation
- Early-onset uterine fibroids requiring surgery before age 40, especially with characteristic histology 1
- Family history of cutaneous leiomyomas, uterine leiomyomas, or renal cell tumors 7
- Multiple leiomyomas (cutaneous or uterine) with symptomatic presentation 3
Testing Approach
For suspected HLRCC: 7
- Perform both sequencing and deletion/duplication testing (e.g., multiplex ligation-dependent probe amplification) in affected individuals
- FH and 2SC immunohistochemistry on tumor tissue shows abnormal staining in >85% of HLRCC-associated tumors and can trigger germline testing 7, 3
- Test at-risk family members starting at age 8 years if familial mutation identified 7
Surveillance for FH Mutation Carriers
Once HLRCC is confirmed, implement: 7
- Annual renal MRI starting age 8 (using targeted renal protocol with diffusion-weighted imaging)
- Annual full skin examinations from diagnosis
- Annual gynecologic examination from age 20 (or earlier if symptomatic) to assess for uterine fibroids and concerning changes
Critical Clinical Pitfalls
The major pitfall is under-recognition of HLRCC in gynecologic practice. Despite family history of HLRCC-related features in 88.8% of patients, only 0.6% undergo germline FH testing before gynecologic diagnosis 3. Integrating age, multiplicity, symptoms, family history, and pathology-triggered FH/2SC immunohistochemistry into routine practice enables earlier identification 3.
For adolescent and young adult sarcoma patients: Only 22% have documented genetics discussions, yet 44% of those tested have identifiable hereditary cancer predisposition syndromes 8. The provider conversation is the critical gateway to genetic referral 8.
Leiomyosarcomas are difficult to distinguish clinically from benign leiomyomas—histopathological examination is essential with a low threshold for excision of suspicious lesions 2, 9.